Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PALB2 inact mut |
| Therapy | Rucaparib |
| Indication/Tumor Type | biliary tract cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 inact mut | biliary tract cancer | sensitive | Rucaparib | Guideline | Actionable | Rubraca (rucaparib) is included in the Pan-Asian Guidelines Adaptation (PAGA) for platinum-sensitive biliary tract cancer patients harboring PALB2 mutations (PMID: 39232586; ESMO.org). | detail... 39232586 |
| PALB2 inact mut | biliary tract cancer | sensitive | Rucaparib | Guideline | Actionable | Rubraca (rucaparib) is included in guidelines as second or later-line therapy for patients with biliary tract cancer harboring PALB2 mutations (PMID: 39864891; ESMO.org). | 39864891 detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| ESMO Clinical Practice Guidelines | Full reference... | |
| ESMO Clinical Practice Guidelines | Full reference... | |
| (39232586) | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer. | Full reference... |
| (39864891) | ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. | Full reference... |